<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1440">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04359290</url>
  </required_header>
  <id_info>
    <org_study_id>KKS-278</org_study_id>
    <nct_id>NCT04359290</nct_id>
  </id_info>
  <brief_title>Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS</brief_title>
  <acronym>RuXoCoil</acronym>
  <official_title>Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the
      treatment of patients with COVID-19 severe pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is an open-label trial of ruxolitinib for the treatment of severe
      COVID-19 to assess its efficacy and safety.

      Ruxolitinib (INCB018424 phosphate, INC424, ruxolitinib phosphate) is a well established,
      potent and selective inhibitor of Janus kinase (JAK)1 and JAK2, with modest to marked
      selectivity against tyrosine kinase (TYK)2 and JAK3, respectively. Ruxolitinib interferes
      with the signaling of a number of cytokines and growth factors that are important for
      hematopoiesis and immune function.

      Ruxolitinib (JAKAVI®) is currently approved in the European Union (EU) for the treatment of
      disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (PMF)
      (also known as chronic idiopathic MF), post-polycythemia vera myelofibrosis (PPV-MF) or
      post-essential thrombocythemia myelofibrosis (PET-MF) and for the treatment of adult patients
      with PV who are resistant to or intolerant of hydroxyurea (HU). In the US, ruxolitinib has
      been approved in the treatment of steroid refractory graft versus host disease post
      allogeneic stem cell transplantation.

      Because many patients with severe respiratory disease due to COVID-19 have features
      consistent with the cytokine release syndrome (CRS) and increased activation of the JAK/STAT
      pathway, it is postulated that ruxolitinib might have a useful role in treating these
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg bid dose at day 1 and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function; open design, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>28 days after registration into trial</time_frame>
    <description>To determine the efficacy of ruxolitinib measured by overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the duration of ventilation support</measure>
    <time_frame>registration until 90 days after registration into trial</time_frame>
    <description>Assessment of the duration of ventilation support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cytokine storm</measure>
    <time_frame>registration until 90 days after registration into trial</time_frame>
    <description>Assessment of the extent of cytokine storm reduction (IL-6, CRP, ferritin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time on ICU</measure>
    <time_frame>registration until 90 days after registration into trial</time_frame>
    <description>To assess time on ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>registration until 90 days after registration into trial</time_frame>
    <description>To assess toxicity and safety of ruxolitinib treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)</measure>
    <time_frame>registration until 90 days after registration into trial</time_frame>
    <description>To assess the timeframe for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function assessed by a CT scan</measure>
    <time_frame>registration until 90 days after registration into trial</time_frame>
    <description>To assess pulmonary function (time point discharge from hospital) by CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>90 days after registration into trial</time_frame>
    <description>To determine the efficacy of ruxolitinib measured by overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>ARDS, Human</condition>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib administration</intervention_name>
    <description>Ruxolitinib will be administered p.o. or by gavage feeding starting with 2 x 10mg bid dose at day 1 and can be increased up to 2 x 15mg bid from day 2 to day 28 (max) (depending on platelet counts and renal function). Ruxolitinib will be administered in the morning and evening. Dosing will be adjusted according to toxicity and kidney function;</description>
    <arm_group_label>Ruxolitinib treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female adult ≥18 years of age at time of enrollment.

          2. laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or
             public health assay (result of the PCR is not necessary for inclusion, but has to
             approved latest within 48-72 hours after registration)

          3. severe lung disease as defined by following:

               1. Recent intubation

               2. Requirement of invasive ventilation moderate to severe pulmonary oxygen exchange
                  disturbance as defined by (PaO2/FiO2) ≤ 200 mmHg at a PEEP ≥ 5mm H2O

               3. Serum LDH &gt; 283 U/l

               4. Ferritin above normal value

               5. CT-scan: pulmonary infiltration compatible with Covid-19 disease

          4. Written informed consent if possible

        Exclusion Criteria:

          1. Uncontrolled HIV infection

          2. Active tuberculosis

          3. Chronic kidney disease requiring dialysis

          4. ALT/AST &gt; 5 times the upper limit of normal.

          5. Pregnancy or breast feeding.

          6. Allergy to study medication

          7. Simultaneous participation in another clinical trial with an experimental treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Neubauer, Prof Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Giessen und Marburg (UKGM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Neubauer, Prof Dr.</last_name>
    <phone>+49 6421 58 66273</phone>
    <email>neubauer@staff.uni-marburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Burchert, Prof Dr.</last_name>
    <phone>+49 6421 58 65611</phone>
    <email>Burchert@med.uni-marburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Andreas Neubauer</name>
      <address>
        <city>Marburg</city>
        <zip>D-35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Neubauer, Prof Dr.</last_name>
      <phone>+49 6421 58 66273</phone>
      <email>neubauer@staff.uni-marburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Burchert, Prof Dr.</last_name>
      <phone>+49 6421 58 65611</phone>
      <email>Burchert@med.uni-marburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003. Chinese.</citation>
    <PMID>32064853</PMID>
  </reference>
  <reference>
    <citation>Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26.</citation>
    <PMID>32105632</PMID>
  </reference>
  <reference>
    <citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;:.</citation>
    <PMID>31986264</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-1174. doi: 10.1002/ppul.24718. Epub 2020 Mar 5.</citation>
    <PMID>32134205</PMID>
  </reference>
  <reference>
    <citation>Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA. 2020 Apr 7;323(13):1313-1314. doi: 10.1001/jama.2020.2131.</citation>
    <PMID>32058570</PMID>
  </reference>
  <reference>
    <citation>[WHO] World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected [Resource on the internet]. 2020 [updated 13 March 2020; cited 24 March 2020]. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected</citation>
  </reference>
  <reference>
    <citation>An Insight of comparison between COVID-19 (2019-nCoV disease) and SARS in pathology and pathogenesis. Author: Xiaolong Cai; Internet posting, of 27-Feb-2020 retrieved 24-Mar-2020. Cite as DOI: 10.31219/osf.io/hw34x</citation>
  </reference>
  <reference>
    <citation>Hermans MAW, Schrijver B, van Holten-Neelen CCPA, Gerth van Wijk R, van Hagen PM, van Daele PLA, Dik WA. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release. Clin Exp Allergy. 2018 Nov;48(11):1412-1420. doi: 10.1111/cea.13217. Epub 2018 Aug 3.</citation>
    <PMID>29939445</PMID>
  </reference>
  <reference>
    <citation>Zhao J, Yu H, Liu Y, Gibson SA, Yan Z, Xu X, Gaggar A, Li PK, Li C, Wei S, Benveniste EN, Qin H. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L868-L880. doi: 10.1152/ajplung.00281.2016. Epub 2016 Sep 16.</citation>
    <PMID>27638904</PMID>
  </reference>
  <reference>
    <citation>Coon TA, McKelvey AC, Lear T, Rajbhandari S, Dunn SR, Connelly W, Zhao JY, Han S, Liu Y, Weathington NM, McVerry BJ, Zhang Y, Chen BB. The proinflammatory role of HECTD2 in innate immunity and experimental lung injury. Sci Transl Med. 2015 Jul 8;7(295):295ra109. doi: 10.1126/scitranslmed.aab3881.</citation>
    <PMID>26157031</PMID>
  </reference>
  <reference>
    <citation>Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model Saad S Kenderian, MD , Blood (2016) 128 (22): 652</citation>
  </reference>
  <reference>
    <citation>Calbet M, Ramis I, Calama E, Carreño C, Paris S, Maldonado M, Orellana A, Calaf E, Pauta M, De Alba J, Bach J, Miralpeix M. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats. J Pharmacol Exp Ther. 2019 Aug;370(2):137-147. doi: 10.1124/jpet.119.256263. Epub 2019 May 13.</citation>
    <PMID>31085698</PMID>
  </reference>
  <reference>
    <citation>The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis Wenjun Wang Jr. et al Internet posting of 27-Feb-2020 retrieved 24-Mar-2020 Cite as: https://doi.org/10.1101/2020.02.26.20026989</citation>
  </reference>
  <reference>
    <citation>Hoffmann J, Machado D, Terrier O, Pouzol S, Messaoudi M, Basualdo W, Espínola EE, Guillen RM, Rosa-Calatrava M, Picot V, Bénet T, Endtz H, Russomando G, Paranhos-Baccalà G. Viral and bacterial co-infection in severe pneumonia triggers innate immune responses and specifically enhances IP-10: a translational study. Sci Rep. 2016 Dec 6;6:38532. doi: 10.1038/srep38532.</citation>
    <PMID>27922126</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>ARDS</keyword>
  <keyword>Ruxolitinib</keyword>
  <keyword>Janus kinase</keyword>
  <keyword>JAK1</keyword>
  <keyword>JAK2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol will be provided after publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>3 Months after publication</ipd_time_frame>
    <ipd_access_criteria>Central server</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

